Verily

2y

Psychiatric trials face the lowest success rates among major therapeutic areas across all clinical trial phases. Only 6.2% of compounds entering psychiatric clinical development get regulatory approval, which leads to lower investment in new treatments. Verily leaders and scientists lay out how digital measures, such as those captured through a wearable or smartphone device, can help address three central challenges in psychiatric trials: ➡️ Psychiatric heterogeneity - by differentiating between patient subtypes via predictive digital biomarkers of treatment response ➡️ Endpoint subjectivity - by providing more objective measures of patient functioning that are related to meaningful aspects of health and that are sensitive to treatment response ➡️ High placebo response rates - by identifying patients that are less likely to respond to placebo via predictive digital biomarkers of placebo response Overall, our team discusses the potential for using digital biomarkers to de-risk psychiatry trials and accelerate treatments and cures for mental health conditions. We are proud to advance this space with the use of Verily Study Watch to capture digital measures in clinical trials across a variety of therapeutic areas, including psychiatry.

Verily

2y

We’re wrapping up a month of activities to celebrate Asian Pacific American Heritage Month. Thank you to our Hyphen ERG for bringing Veeps together and hosting dance workshops, game nights, and an internal talk with Asian leaders at Verily. So fun, inspiring and educational!

Verily

2y

The study detailing our work with WastewaterSCAN to detect H5 in wastewater has been published in ACS Publications. Verily Principal Scientist Bradley White and team quickly developed an assay to detect H5 in wastewater samples in response to uncharacteristic spikes in Influenza A found in wastewater plants in Texas, near H5N1 outbreaks. Tests on wastewater samples revealed the presence of H5 in samples collected shortly before and during the reported cases. The study hypothesizes that H5 is entering municipal wastewater systems through effluent discharged by dairy cattle milk processing plants, which are located within the sewersheds. Our work suggests that wastewater testing can serve as a critical public health monitoring tool by detecting new and emerging pathogens and providing insights. Read more in the paper co-authored by researchers from Rollins School of Public Health at Emory University, Verily and Stanford University School of Engineering.

Verily

2y

Our Chairman and CEO Stephen Gillett discussed Verily’s mission, products and commitment to advancing precision health with Newsweek Investment Reports as part of the annual “New Era of Life Sciences 2024 Report.” “Looking ahead, the integration of advanced AI capabilities into healthcare stands out as a significant opportunity for Verily.”

Verily

2y

"There needs to be a culture of privacy and security, especially in healthcare," said Stephen Gillett, our Chairman and CEO, while on stage at Fortune Brainstorm Health with Bob Segert, Andrea Downing and moderator Andrew Nusca. Stephen also discussed lessons learned from the Change Healthcare breach, including the opportunities for partnerships between the public and private sectors. "Public private partnership will take average or below average security and make it good or great but don't try to do it all yourself."

Verily

2y

This #ClinicalTrialsDay, we celebrate all that has been accomplished to advance medical research thanks to clinical trials and the people behind them. Through Verily Viewpoint, we support research sites and sponsors to make clinical trials more efficient and more representative. Our site clinical trial management system (CTMS) was purpose built for enterprise research sites, designed to digitize study protocols and eliminate siloed manual processes to enable more efficient research, higher-quality output and maximum research revenue. We are committed to supporting clinical trial innovation with these solutions. Thank you to all professionals and participants for your dedication to helping advance treatments and cures.

Verily

2y

Building trust in communities that have been historically underrepresented in clinical studies is an important step to expanding diversity in clinical trials. Andrew Trister, MD PhD, our Chief Medical and Science Officer discussed strategies to make progress while at the recent Milken Institute Global Conference: “Clinical trials are more successful when participants feel like they’re centered in the process. One way to reflect this is in the language associated with clinical trial participation.” “Even the language that we use when we talk about clinical studies represents a change in the hierarchy and shifts how the trust relationship works — a person becomes a subject in a study as opposed to being a patient.”

Verily

2y

Living with a disability can encompass a wide range of experiences. Building accessible and inclusive solutions requires us to consider these needs early in the product development lifecycle so that we build with and for everyone. At Verily, some of our best practices for diversity by design include: ▶ Accessibility and inclusion principles integrated throughout our product design system ▶ User research and focus groups with individuals from historically marginalized communities ▶ Internal awareness and education through our disability-focused employee resource group

Verily

2y

Meet Stephen Gillett, Verily Chairman and CEO, at Fortune Brainstorm Health next Tuesday, May 21. He’ll join Bob Segert of athenahealth, Andrea Downing of The Light Collective, and moderator Andrew Nusca to discuss the growing threat of cybersecurity breaches in the healthcare industry and how to build a resilient health system and ensure patient trust.

Verily

2y

Exciting news for the ALS research community! Target ALS has added comprehensive datasets from its Natural History Study to their data portal. The portal uses Verily Workbench, a collaborative research environment for governing and analyzing global multimodal data to fuel discovery of treatments and biomarkers for ALS.